| PULSE BIOSCIENCES DL-,001 |
| USA |
| Gesundheit |
| US74587B1017 / A2AMY9 |
| 6L8 (Frankfurt) / PLSE (NASDAQ) |
| FRA:6L8, ETR:6L8, 6L8:GR, NASDAQ:PLSE |
| - |
| https://www.pulsebioscien.. |
|
Pulse Biosciences, Inc. is a bioelectric medicine company specializing in the development of novel Nanosecond Pulsed Field Ablation (nsPFA) platforms. Its primary focus centers on the patented nPulse technology, which enables precise, non-thermal abl..
>Volltext.. |
| 2264.55 Mio. EUR |
| 2211.71 Mio. EUR |
| 0.65 Mio. EUR |
| -66.78 Mio. EUR |
| -64.67 Mio. EUR |
| -0.96 EUR |
| 6.2 Mio. EUR |
| 59.25 Mio. EUR |
| -47.87 Mio. EUR |
| 6.97 |
| - |
| -15.9% |
| - |
| - |
| - |
| - |
| PULSE BIOSCIENCES, PULSE BIOSCIENCE, PULSE BIO |
| 06.08.26 |